Key result
Baricitinib retreatment rapidly resolves Kimura's disease relapse following drug discontinuation.
Baricitinib retreatment may lead to rapid response in patients with relapsed Kimura's disease after discontinuation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for baricitinib retreatment in relapsed Kimura's disease; prospective trials needed before clinical adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Teraoka et al. (2026) studied this question. Baricitinib discontinuation led to Kimura's disease relapse, followed by a rapid clinical response upon retreatment.
Synapse has enriched 10 related papers. Consider them for comparative context: